Merck & Co (MRK)
133.72
+0.91 (0.69%)
NYSE · Last Trade: Nov 21st, 4:18 AM EST
Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027fool.com
One of these mRNA pioneers has the products and pipeline to drive growth.
Via The Motley Fool · November 20, 2026
Dow Jones Losers Today: NIKE and UnitedHealth Lead Declineschartmill.com
Via Chartmill · November 19, 2026
Dow Jones Decliners: UNH, NKE, CAT Lead Today's Sessionchartmill.com
Via Chartmill · November 19, 2026
Merck & Co. Eyes Kidney Cancer Data as Vaccine Research Expands Beyond Melanomamarketbeat.com
Merck & Co., Inc. (NYSE:MRK) is studying how its experimental personalized cancer vaccine might work across different tumor types, with kidney cancer data expected to help determine whether the approach can extend beyond tumors with a high number of mutations, a company executive said at the Jef
Via MarketBeat · November 19, 2026
Dow Jones Top Movers: Decliners Lead Nov. 18, 2026 Sessionchartmill.com
Via Chartmill · November 18, 2026
Dow Jones Losers on Nov. 3, 2026: SHW, HD and MRK Lead Declineschartmill.com
Via Chartmill · November 3, 2026
Dow Jones Biggest Decliners in Today's US Sessionchartmill.com
Via Chartmill · November 3, 2026
Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.fool.com
Moderna's melanoma vaccine plus Keytruda cut the risk of recurrence or death by 42% in Phase 3, yet the stock sank. Here's why.
Via The Motley Fool · November 19, 2026
Dow Jones Gainers and Losers: Top Movers in Nov. 18, 2026 US Sessionchartmill.com
Via Chartmill · November 18, 2026
Is Merck's Stock Still a Good Buy at $150?fool.com
The healthcare stock has surged nearly 40% this year.
Via The Motley Fool · November 16, 2026
3 Pharmaceutical Stocks That Offer Safety and Growthmarketbeat.com
AbbVie, Merck and Gilead Sciences offer growing dividends alongside pipeline-driven growth, making pharmaceutical stocks a defensive option as investors seek shelter from market volatility.
Via MarketBeat · November 12, 2026
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boommarketbeat.com
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
Via MarketBeat · November 11, 2026
Moderna Just Gave Investors Yet Another Thing to Cheer Aboutfool.com
Moderna's cancer vaccine has been the big story this year, but its latest quarter showed the rest of its business is improving, too.
Via The Motley Fool · November 6, 2026
2 Growth Stocks to Buy in November Without Any Hesitationfool.com
They have both outperformed the broader equity market over the long run.
Via The Motley Fool · November 5, 2026
History Says This ETF Is a Fantastic Buy-and-Hold Investment -- and It Could Turn $100 per Month Into $359,492fool.com
This dividend ETF has delivered surprisingly strong growth for the past 15 years.
Via The Motley Fool · November 4, 2026
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Successfool.com
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.
Via The Motley Fool · November 3, 2026
3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressivelyfool.com
In 2022, the last time rates rose quickly, these stocks surged, a couple of them by more than 80%.
Via The Motley Fool · November 3, 2026
Tempus AI Surges on Earnings Beat, But Can the Rally Last?marketbeat.com
Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.
Via MarketBeat · November 3, 2026
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugsfool.com
The market for GLP-1 drugs is forecast to explode. It may be understated still.
Via The Motley Fool · November 2, 2026
Why Merck Stock Flew Higher on Fridayfool.com
Investors were still buying it in the afterglow of its latest quarterly earnings release.
Via The Motley Fool · October 30, 2026
MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds
Global pharmaceutical company Merck (NYSE:MRK) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 4.7% year on year to $18.09 bil...
Via StockStory · October 30, 2026
Merck & Co., Inc. Q3 Earnings Call Highlightsmarketbeat.com
Merck & Co., Inc. (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines, cardiometabolic products and animal health helped offset product-specific and market headwinds.
Non-GAAP earnings per share were $2.49 for the quarter,
Via MarketBeat · October 30, 2026
Merck (MRK) Q3 2026 Earnings Call Transcriptfool.com
Generic headwinds ahead in 2027, but new launches and WINREVAIR growth signal momentum.
Via The Motley Fool · October 29, 2026
Dow Jones Top Movers for Oct. 29, 2026: Merck and Nike Lead Gainers, Alphabet and Caterpillar Fallchartmill.com
Via Chartmill · October 29, 2026
Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reactionfool.com
Merck’s new drugs are growing fast enough to cover generic losses, but part of this quarter’s sales gain won’t last. Here’s what to watch.
Via The Motley Fool · October 29, 2026
